Regenerative Medical Technology RMTG
OTC RMTG
$0.03 +0.00 (+0.00%)
At close: Nov 10, 2026 · 4:00 PM EST

Regenerative Medical Technology (RMTG) Liabilities from Discontinued Operations (2021 - 2022)

Updated

Regenerative Medical Technology (RMTG) recorded Liabilities from Discontinued Operations of $68,313 in Q4 2022.

Analysis

Regenerative Medical Technology (RMTG) Liabilities from Discontinued Operations (2021 - 2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Regenerative Medical Technology 412,169.03 -4.11 Mn 2.58 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 68,313.00
Dec 31, 2021 69,314.00
API Access

Regenerative Medical Technology Liabilities from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-from-discontinued-operations&ticker=RMTG&period=max&api_key=YOUR_API_KEY